CONCLUSION
Recurrent uLMS are a rare group of
tumors with an aggressive behavior and poor outcomes. The current study
shows that secondary cytoreductive surgery is an important treatment
choice for these patients and seems to have benefited patients. Time to
fist recurrence within 12 months is an independent predictor of
decreased 5-year OS in SCS subgroup. It’s important to identify the
suitable candidate for SCS. A prospective large study is warranted to
validate these findings.